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Abstract
Head computed tomography (CT) imaging is still a commonly obtained diagnostic test for patients with minor head injury
despite availability of clinical decision rules to guide imaging use and recommendations to reduce radiation exposure
resulting from unnecessary imaging. This prospective multicenter observational study of 251 patients with suspected mild
to moderate traumatic brain injury (TBI) evaluated three serum biomarkers’ (glial fibrillary acidic protein [GFAP],
ubiquitin C-terminal hydrolase-L1 [UCH-L1] and S100B measured within 6 h of injury) ability to differentiate CT
negative and CT positive findings. Of the 251 patients, 60.2% were male and 225 (89.6%) had a presenting Glasgow Coma
Scale score of 15. A positive head CT (intracranial injury) was found in 36 (14.3%). UCH-L1 was 100% sensitive and
39% specific at a cutoff value >40 pg/mL. To retain 100% sensitivity, GFAP was 0% specific (cutoff value 0 pg/mL) and
S100B had a specificity of only 2% (cutoff value 30 pg/mL). All three biomarkers had similar values for areas under the
receiver operator characteristic curve: 0.79 (95% confidence interval; 0.70–0.88) for GFAP, 0.80 (0.71–0.89) for UCH-L1,
and 0.75 (0.65–0.85) for S100B. Neither GFAP nor UCH-L1 curve values differed significantly from S100B ( p = 0.21 and
p = 0.77, respectively). In our patient cohort, UCH-L1 outperformed GFAP and S100B when the goal was to reduce CT
use without sacrificing sensitivity. UCH-L1 values <40 pg/mL could potentially have aided in eliminating 83 of the 215
negative CT scans. These results require replication in other studies before the test is used in actual clinical practice.
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Introduction
Computed tomography (CT) is a frequently used diagnostictest for patients with mild and moderate traumatic brain injury
(TBI), but it is considered to be unnecessary for many patients.1,2
Overuse of CT for evaluating patients with mild TBI (mTBI) has
continued despite the availability of clinical decision rules,3,4 in-
creasing awareness of potential hazards of ionizing radiation ex-
posure,5,6 and some professional society’s recommendations to
reduce CT imaging.7 This has led to a search for an easily obtained
and objective test that can, in the early post-injury period and with
high sensitivity, predict which patients with mTBI will have an
acute intracranial lesion found on head CT. A highly sensitive test,
even with only moderate specificity, would provide clinicians with
a new tool that would be useful in reducing CT use for patients with
suspected mTBI.
Over the last two decades, there has been increasing interest in
several serum proteins that could potentially predict the presence of
a brain injury from head trauma. These proteins are released as a
result of blunt or rapid deceleration forces to the head that cause
injury to the neurons and supporting glial cells. The most widely
studied biomarker for this purpose is S100B,8–15 a protein that is
released after astroglial injury.16 It has been suggested that a S100B
biomarker level below a threshold level can safely eliminate the
need to obtain a CT scan in patients with mTBI.17
The Scandinavian Neurotrauma Committee 2013 guidelines for
the management of minimal, mild, and moderate head injuries in
adults included the use of S100B as a blood sample derived
screening test for CT-proven traumatic intracranial hemorrhage
(ICH).17 In the United States, however, this has not yet been widely
accepted and has not seen broad clinical use. The American College
of Emergency Physicians (ACEP) clinical policy for neuroimaging
and decision making for adults with mTBI in 2008 gave a ‘‘Level C’’
recommendation for the use of S100B as a screening tool to assess
the need for CT imaging in patients with mTBI and no other extra-
cranial injuries,7 but the 2012 Eastern Association for the Surgery
of Trauma guidelines stated that there was not enough evidence to
warrant reliance on S100B to determine the need for head CT.18
More recently, other biomarkers have begun to receive more
attention for a potential role in detecting brain injury. These include
glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-
terminal hydrolase-L1 (UCH-L1). GFAP is a protein expressed in
astroglia cells, but unlike S100B, GFAP is not found in significant
amounts in extracerebral cells.16 Previous studies have demon-
strated that elevated levels of GFAP in patients with mTBI are
associated with abnormal findings on imaging of the brain,12 can
predict the need for surgical intervention,19 and are able to dif-
ferentiate between patients in motor vehicle crashes with ortho-
pedic injuries and those who had mTBI.19 McMahon and
associates20 recently reported that elevated levels of GFAP mea-
sured within the first 24 h after injury could help reduce unneces-
sary CT scans without sacrificing sensitivity in cohorts including
patients with mild, moderate, and severe TBI and may outperform
S100B for the detection of intracranial lesions on CT for patients
with mild TBI.13
UCH-L1 is a deubiquitinase present in neurons.14,21 Elevated
serum levels of this protein have been correlated with brain injury
and clinical outcome.22 There is some evidence for GFAP but only
little evidence for UCH-L1 regarding the early diagnostic utility of
these biomarkers in patients with mTBI, and these studies include
only small numbers of patients with head CT positive acute intra-
cranial lesions.23
Given the limitations of S100B as an ideal single biomarker for
pre-CT screening of patients with mTBI, it was postulated that
other biomarkers, such as GFAP and UCH-L1, could be useful in
screening for acute intracranial lesions among patients with mTBI.
Therefore, the goal of this pilot study was to conduct the first
evaluation of the early (within 6 h of injury) diagnostic character-
istics of GFAP and UCH-L1 to exclude the presence of acute in-
tracranial lesions on head CT in adult patients with mTBI. We also
compared the diagnostic characteristics of UCH-L1 and GFAP with
S100B. These results will be used to derive potential threshold
values for screening patients with mTBI to determine the need for a
head CT scan.
Methods
Patients and study procedures
This prospective multicenter observational study included pa-
tients 18–80 years of age who were evaluated and treated at one of
seven study site hospital emergency departments (EDs) for a blunt
closed head injury and potential mild to moderate TBI. The hos-
pitals were composed of Level 1 and 2 trauma centers, a nontrauma
center, and included both U.S. and European sites (Table 1). Eli-
gible patients were those with an initial Glasgow Coma Scale
(GCS) score of 9–15 who underwent emergency head CT scan for
evaluation of the head injury as deemed necessary by the attending
ED physician.
No formal rules for obtaining a CT were used so as to best reflect
current practice in the United States or Europe, but all sites were
aware of and considered available clinical decision rules to guide
the need for brain imaging. Included patients presented within 4 h
of injury, completed the required CT scan as part of routine care,
Table 1. Description of Study Site Hospitals
Study site Location Annual ED volume Designation
Washington University, Barnes-Jewish Hospital St. Louis, MO 95,000 Level I
University of Florida, Shands Hospital Gainesville, FL 66,000 Level I
Gwinnett Medical Center–Lawrenceville Atlanta, GA 100,000 Level II
Dekalb Medical–North Decatur Atlanta, GA 92,000 Non-trauma
Wayne State–Detroit Receiving Hospital Detroit, MI 90,000 Level I
University of Pe´cs Medical Center Pecs, Hungary 25,000O Level 1*
Albert Szent-Gyo¨rgyi Medical Center–University of Szeged Szeged, Hungary 90,000 Level 1*
ED, emergency department.
OThe ED volume is >25,000/year, and the facility cares for more than 2000 neurotrauma cases/year.
*This is equivalent to a Level 1 facility in the United States.
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and had blood drawn for analysis within 6 h of injury. Table 2
details the full inclusion and exclusion criteria.
Institutional Review Board approval was obtained at each study
site, and each site also obtained approval by the ethics board of the
U.S. Army Medical Research and Materiel Command (USAMRMC)
Office of Research Protections (ORP) Human Research Protection
Office (HRPO) Department of Defense. Baseline patient data col-
lected included demographics, medical history, substance use, GCS
scores, and circumstances related to and the mechanism of injury. This
was used to describe the study patient’s general characteristics only.
Serum sampling and handling
Blood samples were collected at time of study enrollment and
every 6 hours up to the time of discharge (either ED or hospital) or
up to 24 h (maximum of five samples during index visit). Patients
who were seen at follow-up (Day 35 – 5 days) had another sample
obtained when feasible. Blood samples were processed and the
resulting serum was stored at -80C and then shipped on dry ice to
a central repository for storage until time of testing as per a pre-
defined specimen handling procedure.
Serum analysis for GFAP, UCH-L1, and S100B
Serum samples were analyzed for UCH-L1 and GFAP concen-
tration by the Banyan enzyme-linked immunosorbent assay at a later
time by technicians blinded to clinical data and CT results. The
assay was performed as follows: the test sample was added to the
well of a 96-well microtiter plate that had been coated with a capture
antibody specific to the antigen of interest (UCH-L1 or GFAP).
Following a set incubation period during which any antigen present
in the sample binds to the capture antibody, unbound material was
removed by washing with buffer. Horseradish peroxidase (HRP)-
conjugated detection antibody was then added to the well, binding to
a second site on the antigen. Following a set incubation period,
excess detection antibody was removed by washing with buffer.
A chemiluminescent substrate was then added to the well. The
HRP enzyme catalyzes a specific reaction with the chemilumi-
nescent substrate, which produces light that was detected with a
96-well plate-based luminometer. The amount of light generated is
proportional to the amount of detection antibody and thus UCH-L1
or GFAP in the test sample and was compared with light generated
from wells containing known antigen concentrations representing a
calibration curve. Samples were tested in duplicate, and high and
low positive controls were included with each plate. The lower
limit of quantification (LLOQ) and lower limit of detection
(LLOD) for UCH-LI are £30 pg/ml and £10 pg/mL and for GFAP
£30 pg/ml and £20 pg/mL, respectively.
S100B concentrations were determined using an electro-
chemiluminescence immunoassay designed for in-vitro diagnostic
testing (Roche, Cobas 6000). Results are given as S-S100 in lg/L
with the standard normal reference intervals of 0.00–0.09 lg/L.
Although various cutoff values have been proposed, for the pur-
poses of this study, an S100B ‡0.10 lg/L (100 pg/mL) was con-
sidered to be abnormal and could indicate a traumatic abnormality
on head CT.17,24
Assay results were not available to the treating clinician and were
not used to guide treatment. For this main analysis, we only considered
results for the first sample collected within 6 h of injury. For all bio-
markers, results were reported in picograms/milliliter (pg/mL). Be-
cause other studies used different units of measurement—we provided
the units in the original referenced manuscripts and the equivalent
in pg/mL for the above S100B sample measurement section and in
the following results and discussion section where needed.
Head CT scans
Each subject’s head CT images were reviewed by an indepen-
dent committee consisting of three blinded board-certified neuro-
radiologists. The neuroradiologists determined whether a CT scan
was positive—defined as the presence of an acute trauma-related
intracranial lesion. Table 3 lists the criteria for what was deemed a
positive finding. A procedure outlining the criteria and process to
be followed for scoring the CT scans was developed before the
reading and interpretation of any of the CT images. Two of the
neuroradiologists who had no access to any other clinical or labo-
ratory data, except subject age and sex, reviewed all of the study
subjects’ CT scans. Any discrepancy with respect to CT-positive or
Table 2. Inclusion/Exclusion Criteria
Inclusion criteria
 The subject was ‡18 years of age and no more than 80 years
of age.
 Acceleration or deceleration closed injury to the head that
was either self-reported or witnessed.
 Presented to an emergency department (ED) within 4 h of injury.
 An initial Glasgow Coma Scale score of 9–15 in the ED
performed by the Principal Investigator (PI) or trained study
personnel.
 ED workup included a head computed tomography (CT) scan
(based on standard practice and/or decision rules).
 Informed consent was obtained from the subject or his or her
legal representative; oral consent for the initial blood draw
and/or deferred consent to 24 h was allowed for patients who
were unable to consent at initial evaluation or exception from
the informed consent requirement by use of ‘‘community
consent’’ if approved by an Institutional Review Board.
 The PI deemed the subject to be an appropriate study
candidate.
Exclusion criteria
 Participation in another clinical study that may affect the
results of either study.
 Time of injury was not able to be accurately determined.
 Head CT not done as part of clinical emergency care.
 Primary diagnosis of ischemic or hemorrhagic infarct.
 Not available for 35 day follow-up visit.
 Venipuncture not feasible.
 Blood donation within 1 week of screening.
 The subject was otherwise determined medically unsuitable
for study participation.
Table 3. Definition of Acute Intracranial Lesion
Acute intracranial lesion is defined as any trauma induced or
related finding. Acute lesions may include the following and
the number of each finding:
N
Extra-axial lesions
 Acute epidural hematoma (EPH) 3
 Acute subdural hematoma (SDH) 21
Cortical contusion 10
Ventricular compression 3
Ventricular trapping 0
Brain herniation 0
Intraventricular hemorrhage 1
Hydrocephalus 1
Subarachnoid hemorrhage 27
Petechial hemorrhagic or bland sheer injury 0
Brain edema 0
Post-traumatic ischemia 0
Intracerebral hematoma 0
Dural venous sinus injury and/or thrombosis 0
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CT-negative was adjudicated by a third blinded radiologist and, in
those instances, was the final interpretation. Interrater reliability
between the two primary radiologists was determined using the
Cohen Kappa statistic.
Outcomes
For this study, the primary clinical outcome of interest was the
results of the head CT scan (positive/negative) among patients with
the first blood sample drawn within 6 h of injury.
Data analysis and reporting
A descriptive analysis for all subjects was performed. Patient
groups (CT positive and CT negative) were described using pro-
portions and means or medians where appropriate. For data analyses,
any biomarker value below the detectible limit was coded as 0 pg/mL.
The exception to this was for the scatter plots that used a log linear
y-axis for which a value of 0.01 pg/mL was used (0 pg/mL is not a
valid value using the log scale). The Spearman correlation coef-
ficients were calculated for each biomarker pairing. Logistic re-
gression was used to determine area under the receiver operator
characteristic (AUROC) curve for all three biomarkers indepen-
dently and also for a single model with all three biomarkers col-
lectively. Probability output from the logistic regression models
and graphical displays were used to evaluate clinically relevant
cutoff values for positive and negative values for GFAP, UCH-
L1, and S100B.25 A nonparametric approach was used to com-
pare the correlated ROC curves without adjustments for pairwise
comparisons.26
Sensitivity and specificity were calculated for the primary and
secondary outcomes. Because there would be little acceptance of
missed injury on CT scan, our goal was to maximize sensitivity to
100% at the expense of specificity. This allowed for determination
of the number of CT scans that could potentially be safely elimi-
nated when screening using each biomarker. We also examined
threshold values that would result in sensitivity ‡95% and ‡90% for
comparison of specificity.25 For GFAP and UCH-L1, we calculated
individual sensitivity and specificity values. We also implemented
a combined biomarker strategy: if either GFAP was ‡100 or UCH-
L1 ‡40 (chosen based on our data for optimal UCH-L1 sensitivity),
the test was considered positive. For the reporting of S100B, we
used the Scandinavian recommendation of >0.10 lg/L (100 pg/mL)
for patients injured within 6 h of serum sampling as the standard
cutoff value.17
A sensitivity analysis (in this instance meaning varying the as-
sumptions of the diagnostic tests) that examined patients with an
initial sample obtained within 4 h (ACEP guidelines) of injury was
performed to evaluate for diagnostic capability of the biomarkers at
times closer to injury and times that may be more favorable to the
standard S100B values.7 Because the cut points for UCH-L1 and
GFAP were optimized to our data, we also re-examined the
AUROC curves and graphical data to determine whether a different
cut point value for S100B would improve the diagnostic capability
of that test for our data. This was done so not to ‘‘favor’’ the new
diagnostic markers (GFAP and UCH-L1) over S100B.
There were no formal hypotheses for this study, and it was not
designed to provide a definitive assessment of the studied bio-
markers’ test characteristics. The study was, rather, descriptive and
exploratory in nature, and the results will be used as an adjunct to
help derive biomarker cutoff values for a future validation trial. The
analysis included proportions with associated exact Clopper-
Pearson 95% confidence intervals (CIs), means with standard de-
viation (SD), and medians with 25th and 75th percentiles where
appropriate. The p values were only used for comparing AUROC
curve data.
Recommended guidelines for reporting results of diagnostic
tests were followed.27,28 These results are not to be considered as
evidence to reject a null hypothesis. All data analyses were per-
formed using SAS 9.4 and R 3.1.0.
Results
The study enrolled 290 patients; 26 were initially excluded for a
variety of reasons, leaving a total of 264 patients who had data for at
least one blood sample and the required CT results. Excluded were
13 more subjects because the initial blood sample draw was past the
6-h time window, leaving a study sample size of 251 patients for
this main analysis. Of those, only 231 subjects had an adequate
sample volume for the analysis of all three markers (20 patients did
FIG. 1. Flow diagram describing excluded and included patients with mild to moderate traumatic brain injury. CT, computed
tomography; UCH-L1, ubiquitin carboxyl-terminal hydrolase-L; GFAP, glial fibrillary acidic protein.
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not have enough blood sample volume to test S100B). Figure 1
outlines the study patient selection process.
The mean age of all patients was 45.6–18.4 years and 60.2%
(95% CI; 53.8%–66.3%) were male. The main mechanisms of injury
were falls and/or motor vehicle crashes. Of the 251 observations, 206
observations were classified as negative by both primary radiologists,
33 were classified as positive by both primary radiologists, and 12
received discrepant positive and negative classifications from the two
primary radiologists (95% agreement; Kappa=0.82, 95% CI 0.71–
0.91). After final diagnosis, adjudicated by a third independent radi-
ologist, 36 patients (14.3%; 95% CI 10.3%–19.3%) had a CT scan
that was positive for an acute intracranial lesion. Table 3 shows the
findings among patients with positive head CT scan results. Note that
the number of findings add up to more than 36 because many patients
had more than one CT abnormality.
All except one of the head CTs were positive for some type of
blood (ICH); one patient had a nonhemorrhagic contusion. Of the 251
study patients, 225 (89.6%; 95% CI 85.2%–93.1%) had an initial
GCS of 15 of whom 24 (10.7%) had a positive CT scan. Among
patients with a GCS <15 (n= 26), 12 (46.2%) had a positive CT scan.
Median values for all biomarkers were higher among CT positive
patients. Table 4 details these and other patient characteristics.
The Spearman correlation coefficients were 0.49 for GFAP and
UCH-L1, 0.37 for GFAP and S100B, and 0.77 for UCH-L1 and
Table 4. Patient Characteristics
CT negative 85.7% (total n = 215) CT positive 14.3% (total n= 36) All subjects (total n = 251)
Age (mean – SD) 44.3 – 18.1 53.7 – 17.7 45.6 – 18.4
Sex
Female 41.4% (89) 30.6% (11) 39.8% (100)
Male 58.6% (126) 69.4% (25) 60.2% (151)
Race
White 66.5% (143) 91.7% (33) 70.1% (176)
Black 27.4% (59) 2.8% (1) 23.9% (60)
Other 6.1% (13) 5.6% (2) 6.0% (15)
Employment status (n= 243)
Employed 47% (98) 41% (14) 46% (112)
Unemployed 23% (49) 18% (6) 23% (55)
Student 9% (19) 0% (0) 8% (19)
Homemaker 1% (3) 0% (0) 1% (3)
Retired 19% (40) 41% (14) 22% (54)
Alcohol
Yes 24.2% (52) 33.3% (12) 25.5% (64)
No 75.8% (163) 66.7% (24) 74.5% (187)
Drugs
Yes 15.4% (33) 5.6% (2) 13.9% (35)
No 84.7% (182) 94.4% (34) 86.1% (216)
Smoke
Yes 31.6% (68) 33.3% (12) 31.9% (80)
No 68.4% (147) 66.7% (24) 68.1% (171)
Mechanism of injury (n = 250)O
MVC 39% (84) 17% (6) 35.9% (90)
Assault 12% (25) 11% (4) 11.6% (29)
Fall 50% (107) 75% (27) 53.4% (134)
Sports 3% (7) 0% (0) 2.8% (7)
Loss of consciousness (LOC)
Yes 63.7% (137) 75.0% (27) 65.3% (164)
No 32.6% (70) 19.4% (7) 30.7% (77)
Unknown 3.7% (8) 5.6% (2) 4.0% (10)
LOC information (n = 250)
Self-reported 57.0% (122) 36.1% (13) 53.8% (135)
Witnessed 43.0% (92) 63.9% (23) 45.8% (115)
GCS
15 93.5% (201) 66.7% (24) 89.6% (225)
14 5.1% (11) 16.7% (6) 6.8% (17)
13 0.5% (1) 11.1% (4) 2.0% (5)
9–12 0.9% (2) 5.6% (2) 1.6% (4)
GFAP (median; 25th, 75th) 7.8 (2.7, 22.1) 110.5 (20.4, 431.8) 10.3 (3.5, 37.4)
UCH-L1 (median; 25th, 75th) 56.2 (24.4, 104.3) 132.3 (98.2, 269.2) 65.8 (39.6, 125.2)
S100B (median; 25th, 75th) 100 (70, 190) 215 (160, 410) 120 (70, 230)
CT, computed tomography; SD, standard deviation; MVC, motor vehicle collision; GCS, Glasgow Coma scale; GFAP, glial fibrillary acidic protein;
UCH-L1, ubiquitin carboxyl-terminal hydrolase-L.
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FIG. 2. Scatter plots for glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase-L (UCH-L1), and S100B stratified
by computed tomography (CT) results. (A) All biomarker values; (B) biomarker values £1200 pg/mL; (C) biomarker values £400 pg/mL.
Color image is available online at www.liebertpub.com/neu
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FIG. 3. Scatter plots for glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase-L (UCH-L1), and S100B
stratified by presenting Glasgow Coma Scale (GCS) score (all values £400 pg/mL for resolution). (A) GFAP; (B) UCH-L1; (C) S100B.
CT, computed tomography. Color image is available online at www.liebertpub.com/neu
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S100B. There were 45 subjects who had GFAP levels below de-
tectable levels (4 had a positive CT scan), 2 patients had UCH-L1
levels below detection (none had a positive CT scan), and all S100B
values obtained were in the detectible range.
Figure 2A shows scatter plots of the three biomarker results. The
plots include all individual patients stratified by CT result. So the
reader can better examine for potential false-negative values, only
those patients with values less than or equal to 1200 pg/mL (Fig.
2B) and 400 pg/mL (Fig. 2C) for each biomarker are shown. This
effectively reduces the scale on the y-axis for the corresponding
biomarker also stratified by CT scan result. Figures 3A–C show
similar scatter plots for all three biomarkers, but in this case stra-
tified by the Glasgow Coma Scale score; with all values capped at
400 pg/mL for better visual resolution. For these figures, only
biomarker values less than or equal to 400 pg/mL were included
because the lower values are of most importance.
All three biomarkers had similar values for the AUROC curves:
0.75 (95% CI; 0.65–0.85) for S100B, 0.79 (0.70–0.88) for GFAP,
and 0.80 (0.71–0.89) for UCH-L1. When a direct comparison was
performed, neither GFAP nor UCH-L1 differed significantly from
S100B ( p= 0.21 and p = 0.77, respectively; see Fig. 4A–D). The
slight difference in AUROC curve values for the biomarkers when
calculated individually was a result of the logistic regression pro-
cedure excluding 20 patients with missing values for S100B
FIG. 4. Area under the receiver operating characteristic (ROC) curve comparison for all (A) biomarkers in the model (n = 231) and for
each individual marker (n= 251 for glial fibrillary acidic protein [B] and ubiquitin carboxyl-terminal hydrolase-L [C] and n= 231 for
S100B [D]). Color image is available online at www.liebertpub.com/neu
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(complete case analysis), but the results were nearly identical. We
also examined the predictive values of two biomarkers compared
with one marker alone and, regardless of the pairing (for example,
GFAP and UCH-L1 compared with either marker alone), the
AUROC curves were no more predictive than the AUROC curve of
a single biomarker.
Threshold values for the biomarkers were determined for our
study population that provided for high sensitivity at the expense of
specificity. For our primary outcome, UCH-L1 was 100% sensi-
tive and 39% (95% CI 33%–46%) specific at a value ‡40 pg/mL
(specificity was 40%, 95% CI 33%–47% when using a cutoff of
41 pg/mL; Table 5). In contrast, GFAP was 100% sensitive and
0% specific at a cutoff of 0 pg/mL, indicating that using the GFAP
value associated with 100% sensitivity within 6 h of injury, the
test could not reliably determine which patients had negative
head CTs. At a sensitivity of 100%, S100B had a specificity of
only 2%. In addition, S100B was only 91% sensitive and 44%
specific at the recommended 100 pg/mL threshold. The combined
biomarker strategy (both GFAP and UCH-L1) resulted in the
same sensitivity and specificity estimates as that of UCH-L1
alone.
Table 5 provides a summary of the sensitivity and specificity at a
variety of biomarker threshold values (with associated 95% CIs) and
details the threshold biomarker values determined for sensitivity
‡95% and ‡90% and the same resulting test characteristics for pa-
tients evaluated at 4 h post-injury.
Of the three patients with abnormal CT findings that would have
been missed by S100B (<100 pg/mL), one had a subdural hema-
toma; the second patient had a subdural hematoma with a cortical
hemorrhagic contusion and subarachnoid hemorrhage, and the third
had a hemorrhagic contusion with subarachnoid hemorrhage and
depressed skull fracture. For two patients, the mechanism of injury
was a fall and the third was physically assaulted. All three presented
with a GCS score of 15.
When implementing a combined strategy of all three markers
(positive if GFAP ‡100, UCH-L1 ‡40, or S100B ‡100), the re-
sulting sensitivity remained at 100%, but specificity decreased to
0.29 and 0.26 at 6 h and 4 h, respectively (not in table).
Finally, we examined the results for and GFAP and UCH-L1 when
only considering the 231 patients having all biomarker data. For GFAP,
specificity was 0.00, but for UCH-L1, 100% sensitivity was obtained
at a concentration of 40.9 pg/mL (95% CI 0.89–1.00) and sensitivity
was 0.40 (95% CI 0.33 to 0.47), neither reflecting a selection bias.
Discussion
This prospective observational study evaluated three biomarkers
for potential usefulness to exclude an acute intracranial injury
as determined by CT scan in patients with mild to moderate TBI.
Both S100B and GFAP have been studied in patients with mild to
moderate TBI with the former being extensively evaluated. For
UCH-L1, however, only limited information in patients with mTBI
Table 5. Sensitivity, Specificity, and 95% Confidence Intervals for Biomarkers at 6 and 4 Hours Post-Injury
Biomarker
Threshold for a
positive test (pg/mL) Sample size Sensitivity (95% CI) Specificity (95% CI)
6 hoursO GFAP & UCH-L1N 100 GFAP
40 UCH-L1
251 1.00 (0.90, 1.00) 0.39 (0.33, 0.46)
4 hoursO GFAP & UCH-L1N 100 GFAP
40 UCH-L1
251 1.00 (0.89, 1.00) 0.37 (0.30, 0.44)
6 hoursO GFAPU (=100%) 0 251 1.00 (0.90, 1.00) 0.00 (0.00, 0.02)
GFAP (‡ 95%) 0 251 1.00 (0.90, 1.00) 0.00 (0.00, 0.02)
GFAP (‡90%) 0 251 1.00 (0.90, 1.00) 0.00 (0.00, 0.02)
GFAP 15 251 0.81 (0.64, 0.92) 0.67 (0.61, 0.74)
UCH-L1U (=100%) 41 251 1.00 (0.90, 1.00) 0.40 (0.33, 0.47)
UCH-L1 (‡ 95%) 44 251 0.97 (0.85, 1.00) 0.42 (0.36, 0.49)
UCH-L1 (‡ 90%) 67 251 0.92 (0.78, 0.98) 0.58 (0.51, 0.65)
UCH-L1 35 251 1.00 (0.90, 1.00) 0.34 (0.28, 0.41)
S100BU (=100%) 30 231 1.00 (0.89, 1.00) 0.02 (0.00, 0.04)
S100B (‡95%) 80 231 0.97 (0.84, 1.00) 0.30 (0.24, 0.37)
S100B (‡90%) 120 231 0.91 (0.75, 0.98) 0.54 (0.47, 0.61)
S100Ba 100 231 0.91 (0.75, 0.98) 0.44 (0.37, 0.51)
4 hoursO GFAPU (=100%) 0 251 1.00 (0.89, 1.00) 0.00 (0.00, 0.02)
GFAP (‡95%) 0 251 1.00 (0.89, 1.00) 0.00 (0.00, 0.02)
GFAP (>90%) 4 251 0.90 (0.74, 0.98) 0.30 (0.24, 0.37)
UCH-L1U (=100%) 44 251 1.00 (0.89, 1.00) 0.40 (0.33, 0.48)
UCH-L1 (‡95%) 64 251 0.97 (0.83, 1.00) 0.54 (0.47, 0.62)
UCH-L1 (‡90%) 74 251 0.90 (0.74, 0.98) 0.60 (0.53, 0.67)
S100BU (=100%) 80 231 1.00 (0.88, 1.00) 0.28 (0.22, 0.35)
S100B (>95%) 90 231 0.96 (0.82, 1.00) 0.36 (0.29, 0.44)
S100B (‡90%) 120 231 0.93 (0.76, 0.99) 0.53 (0.45, 0.60)
S100Ba 100 231 0.93 (0.76, 0.99) 0.42 (0.34, 0.49)
CI, confidence interval; GFAP, glial fibrillary acidic protein; UCH-L1, ubiquitin carboxyl-terminal hydrolase-L1
NIf either GFAP UCH-L1 was above the threshold, it was considered to be a positive test. If both were below the threshold, the test was negative.
OTime from reported injury to blood sample obtained.
USensitivity and specificity results for each target sensitivity level (100%, ‡95%, and ‡90%) and resulting biomarker threshold values.
aThis is at the recommended threshold of 100 pg/mL for S100B.
GFAP, UCHL-1, AND S100B TO CLASSIFY HEAD CT FINDINGS 211
is available, particularly related to early screening for CT abnor-
malities in patients with mild to moderate TBI.
Therefore, we conducted the first study designed to evaluate test
characteristics of the three biomarkers in the same patient cohort
with the goal of determining optimal testing strategies and applying
the results to a larger cohort of patients with mild to moderate TBI.
Our results demonstrate that early biomarker screening for patients
with mild to moderate TBI potentially can provide the clinician
with objective evidence needed to reduce CT use.
This study was not designed to determine biomarker capability
to differentiate patients with or without any brain injury but rather
to differentiate patients with head injury who have a negative
versus positive head CT scan. Therefore, it is likely patients en-
rolled in this study who had a negative head CT scan could still
have had neuronal and glial cellular damage that resulted in ele-
vated biomarker levels. This and other factors may have led to the
high degree of overlap in biomarker levels (particularly with GFAP
and S100B) between CT negative and CT positive patients. In fact,
a recent study reported that MRI during the subacute phase (1–2
weeks) post-injury detected injuries in more than 20% of patients
who had negative CT finding on initial evaluations. This indicates
that blood biomarkers coupled with advanced MRI imaging are
complimentary in the diagnosis of mTBI cases.20,29
Because there is no true ‘‘gold-standard’’ for the early diagnosis
of mTBI, there still may be utility in considering the possibility that
patients with elevated biomarkers may have sustained actual brain
injury despite having a negative CT scan. This concept requires
further study.
Of the three biomarkers evaluated in this study, UCH-L1 had the
best test performance when used to differentiate between subjects
with normal versus abnormal CTs. Within 6 h of injury, a UCH-L1
level above 40 pg/mL detected all 36 patients with an acute intra-
cranial lesion as determined by a reference CT scan. Given the
estimate of 39% specificity, we could have potentially eliminated
83 (95% CI 70–98 scans) of the 215 negative CT scans performed
in our study population. The sensitivity and specificity when com-
bining GFAP and UCH-L1 was the same as UCH-L1 alone, indi-
cating that UCH-L1 was the driving biomarker at the given 6-h time
interval. The value of these tests appears to be in the ability of a
specified threshold value to reduce the need to obtain a head CT
(‘‘rule-out’’ an abnormal CT) among patients with mild to moderate
TBI as opposed to using a high value to ‘‘rule-in’’ a positive scan.
Three patients with abnormal CT findings would have been missed
by S100B (<100 pg/mL) at the 6-h time limit. These three patients
presented with a GCS score of 15, had important injuries, and would
require at least observation. Because this study was not designed to
determine need for surgery, we do not know whether the patients
required surgery or other invasive neurosurgical procedures.
Analysis of biomarker test characteristics using AUROC curve
analysis did not reveal any significant difference between S100B
and either UCH-L1 or GFAP. AUROC curves, however, reflect the
combination of sensitivity and specificity across the entire range of
each. Rather than focusing on a single summary statistic such as the
AUROC curve, it is often more useful to define the most important
aspect of the test being studied.27,28,30
For our study, we determined that test sensitivity was the critical
test characteristic, and lower levels of specificity would be tolerated.
This was because of the a priori decision that the defined screening
tests should miss little to no cases of acute intracranial lesions. It was
hoped that with optimal sensitivity, that the specificity of the bio-
marker would still be high enough to safely reduce the number of
negative CT scans and the tests would be acceptable to practicing
physicians. Although on this derivation cohort, UCH-L1 had 100%
sensitivity with a fairly good (39%) specificity, the study sample
size was not large enough to have a high level of certainty, and a
validation study on a larger patient cohort is warranted.
The Scandinavian guidelines for treating adult patients with mild
to moderate head injury recommend S100B as an alternative to
head CT when evaluating low-risk patients with either a presenting
GCS of 14 or a GCS of 15 with suspected or confirmed loss of
consciousness or persistent vomiting.17 For our patients, S100B
was 91% sensitive when using the recommended threshold value of
100 pg/mL at 6 h post-injury.
Lowering the threshold for S100B to 30 pg/mL at 6 h allowed
100% sensitivity (95% CI 90–100) but had a specificity of only 2%
(95% CI 0–4), making the test ineffective for decreasing the use of
head CT in this setting. At 80 pg/mL, however, the sensitivity at 6 h
was 97% (with a specificity of 30%, and at 4 h, this same value had
a sensitivity of 100%, with a specificity of 28%. Both of these
specificities are less than the 39% specificity of UCH-L1 at the
cutoff value of 40 pg/mL.
Given the results of previous studies,13,20 it was somewhat sur-
prising that GFAP did not perform as well, but this may be because
the samples were collected before the bigger rise in serum GFAP
levels (data not shown). One recent study suggested that elevated
GFAP levels provided a diagnostic benefit above clinical screening
alone, but this study included GFAP results that were obtained up to
24 h after mild, moderate, and severe TBI.20 Our study included
only patients with mild and moderate TBI who were evaluated
much earlier (within 6 h of injury), making our results more ap-
plicable and useful for ED screening for abnormal CT scans in
patients with head injuries.
Results of biomarker testing performed within 4 h of injury
showed a similar sensitivity for UCH-L1 with specificity that re-
mained reasonably good (37%). For S100B at the same 4 h time
window, sensitivity was 93% (lower 95% CI 76%) and specificity
was 42%. Although this specificity would reduce the number of
unnecessary CT scans, the lower sensitivity is unlikely to be ac-
ceptable to justify the elimination of head CTs in these patients.
Experts and professional societies have suggested that the in-
creasing use of head CT to evaluate patients with mTBI is unjus-
tified.1,2,7,17 Clinical decision rules that can guide physicians on the
use of head CT are well developed and studied3,4,31,32 but have not
seemed to result in decreased utilization of inappropriate CT ex-
aminations among patients with mTBI.1,33
A simple, sensitive, and rapid screening test that could be used in
conjunction with validated clinical decision rules has the potential
to reduce the use of CT scans for patients with mTBI and the
associated radiation exposure and financial costs. It has been sug-
gested that radiation has the potential to cause a small increased
cancer risk to humans.5 Recognition of these potential risks has
resulted in an initiative by the Food and Drug Administration to
reduce radiation exposure as well as publish practice guidelines to
minimize unnecessary CT examinations.34
The results of the current study provide evidence that assess-
ments of serum levels of GFAP and UCH-L1 may achieve this goal
by predicting, with a high sensitivity, acute intracranial lesions
detected by CT while still preserving sufficient specificity to pro-
vide an important reduction in CT use.
Limitations
There were a number of limitations that must be considered
when evaluating this study and its results. Because this study was
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designed to evaluate potentially optimal cutoff values for the bio-
markers, performance of the biomarkers may be inflated. Derived
CIs for specificity (and proportion of eliminated unnecessary CT
scans) was conditioned on both the subjective decision of the CT
scan and on the choice of an appropriate threshold with 100%
sensitivity, and do not reflect the variability inherent in those two
processes. External validation of these potential thresholds is
needed to assess the robustness of these findings.
Our study found that patients presenting with an initial GCS <15
had a high proportion of positive head CTs. Over a third of patients
(6 of 17) with a GCS of 14 had positive scans. This is likely because
of our small number of patients and the relatively high percentage
of positive CT scans and may not represent the usual group of
patients with mTBI who present with an initial GCS of 14. Gen-
eralizability of these results is limited to the study population—i.e.,
patients with an initial GCS of 9–15 who would typically be re-
commended by the ED physician for emergency head CT scan.
The definition of a positive CT included findings other than just
traumatic ICH, but we did exclude isolated skull fracture from the
definition. Practice variation led to the inclusion of a relatively high
percent of patients with positive head CTs relative to that of pa-
tients enrolled in U.S. sites. Given patients were enrolled in the
United States and in Europe, selection of patients varied across
sites. The majority of subjects had a GCS of 15, so these results may
not apply to patients with a GCS score less than 15.
Finally, this study was not designed to determine clinical outcomes
such as need for neurosurgical intervention or death but rather just to
determine the association of specific biomarker values with a positive
finding on head CT—an important first step in reducing CT use.
Conclusion
Our data suggest that when obtained within 6 h of injury, UCH-
L1 and the combination of GFAP and UCH-L1 (at our pre-defined
cutoff values) were very sensitive for a positive CT scan of the head
among patients with mild to moderate TBI. If confirmed in a large
trial with greater numbers of positive CT scans, UCH-L1 and the
combination of GFAP and UCH-L1 could provide the objective
evidence clinicians desire to reduce the use of CT scans among
patients with mTBI. Further study related to other times post-injury
and the utility of repeated test measurements will help further
clarify the utility of these biomarkers.
Acknowledgment
This work is supported by the U.S. Army Medical Research and
Material Command under Contract N. W81XWH-06-1-0517 and
Contract N. W81XWH-10-C-0251. The views, opinions and/or
findings contained in this report are those of the authors and should
not be construed as an official Department of the Army position,
policy or decision unless so designated by other documentation.
ClinicalTrials.gov Identifier: NCT01295346.
Banyan Biomarkers, Inc. personnel include Art Weber, Anna
Shoshoo, Mike Catania, and Aarti Chawla.
Author Disclosure Statement
No competing financial interests exist.
References
1. Melnick, E.R., Szlezak, C.M., Bentley, S.K., Dziura, J.D., Kotlyar, S.,
and Post, L.A. (2012). CT overuse for mild traumatic brain injury. Jt.
Comm. J. Qual. 38, 483–489.
2. Korley, F.K., Morton, M.J., Hill, P.M., Mundangepfupfu, T., Zhou, T.,
Mohareb, A.M., and Rothman, R.E. (2013). Agreement between
routine emergency department care and clinical decision support re-
commended care in patients evaluated for mild traumatic brain injury.
Acad. Emerg. Med. 20, 463–469.
3. Stiell, I.G., Wells, G.A., Vandemheen, K., Clement, C., Lesiuk, H.,
Laupacis, A., McKnight, R.D., Verbeek, R., Brison, R., Cass, D.,
Eisenhauer, M.E., Greenberg, G., and Worthington, J. (2001). The
Canadian CT Head Rule for patients with minor head injury. Lancet
357, 1391–1396.
4. Haydel, M.J., Preston, C.A., Mills, T.J., Luber, S., Blaudeau, E., and
DeBlieux, P.M. (2000). Indications for computed tomography in pa-
tients with minor head injury. N. Engl. J. Med. 343, 100–105.
5. Smith-Bindman, R., Lipson, J., Marcus, R., Kim, K.P., Mahesh, M.,
Gould, R., Berrington de Gonzalez, A., and Miglioretti, D.L. (2009).
Radiation dose associated with common computed tomography ex-
aminations and the associated lifetime attributable risk of cancer.
Arch. Intern. Med. 169, 2078–2086.
6. Brenner, D.J., and Hall, E.J. (2007). Computed tomography—an in-
creasing source of radiation exposure. N. Engl. J. Med. 357, 2277–
2284.
7. Jagoda, A.S., Bazarian, J.J., Bruns, J.J., Jr., Cantrill, S.V., Gean, A.D.,
Howard, P.K., Ghajar, J., Riggio, S., Wright, D.W., Wears, R.L.,
Bakshy, A., Burgess, P., Wald, M.M., and Whitson, R.R. (2008).
Clinical policy: neuroimaging and decisionmaking in adult mild
traumatic brain injury in the acute setting. Ann. Emerg. Med. 52, 714–
748.
8. Jeter, C.B., Hergenroeder, G.W., Hylin, M.J., Redell, J.B., Moore,
A.N., and Dash, P.K. (2013). Biomarkers for the diagnosis and
prognosis of mild traumatic brain injury/concussion. J. neurotrauma
30, 657–670.
9. Egea-Guerrero, J.J., Revuelto-Rey, J., Murillo-Cabezas, F., Munoz-
Sanchez, M.A., Vilches-Arenas, A., Sanchez-Linares, P., Dominguez-
Roldan, J.M., and Leon-Carrion, J. (2012). Accuracy of the S100beta
protein as a marker of brain damage in traumatic brain injury. Brain
Inj. 26, 76–82.
10. Zongo, D., Ribereau-Gayon, R., Masson, F., Laborey, M., Contrand,
B., Salmi, L.R., Montaudon, D., Beaudeux, J.L., Meurin, A., Dousset,
V., Loiseau, H., and Lagarde, E. (2012). S100-B protein as a screening
tool for the early assessment of minor head injury. Ann. Emerg. Med.
59, 209–218.
11. Biberthaler, P., Linsenmeier, U., Pfeifer, K.J., Kroetz, M., Mussack,
T., Kanz, K.G., Hoecherl, E.F., Jonas, F., Marzi, I., Leucht, P., Jo-
chum, M., and Mutschler, W. (2006). Serum S-100B concentration
provides additional information for the indication of computed to-
mography in patients after minor head injury: a prospective multi-
center study. Shock 25, 446–453.
12. Metting, Z., Wilczak, N., Rodiger, L.A., Schaaf, J.M., and van der
Naalt, J. (2012). GFAP and S100B in the acute phase of mild trau-
matic brain injury. Neurology 78, 1428–1433.
13. Papa, L., Silvestri, S., Brophy, G.M., Giordano, P., Falk, J.L., Braga,
C.F., Tan, C.N., Ameli, N.J., Demery, J.A., Dixit, N.K., Mendes,
M.E., Hayes, R.L., Wang, K.K., and Robertson, C.S. (2014). GFAP
out-performs S100beta in detecting traumatic intracranial lesions on
computed tomography in trauma patients with mild traumatic brain
injury and those with extracranial lesions. J. Neurotrauma 31, 1815–
1822.
14. Yokobori, S., Hosein, K., Burks, S., Sharma, I., Gajavelli, S., and
Bullock, R. (2013). Biomarkers for the clinical differential diagnosis
in traumatic brain injury—a systematic review. CNS Neurosci Ther.
19, 556–565.
15. Muller, K., Townend, W., Biasca, N., Unden, J., Waterloo, K.,
Romner, B., and Ingebrigtsen, T. (2007). S100B serum level predicts
computed tomography findings after minor head injury. J. Trauma 62,
1452–1456.
16. Zetterberg, H., Smith, D.H., and Blennow, K. (2013). Biomarkers of
mild traumatic brain injury in cerebrospinal fluid and blood. Nat. Rev.
Neurol. 9, 201–210.
17. Unden, J., Ingebrigtsen, T., Romner, B.; Scandinavian Neurotrauma
Committee. (2013). Scandinavian guidelines for initial management of
minimal, mild and moderate head injuries in adults: an evidence and
consensus-based update. BMC Med. 11, 50.
18. Barbosa, R.R., Jawa, R., Watters, J.M., Knight, J.C., Kerwin, A.J.,
Winston, E.S., Barraco, R.D., Tucker, B., Bardes, J.M., and Rowell,
S.E. (2012). Evaluation and management of mild traumatic brain
GFAP, UCHL-1, AND S100B TO CLASSIFY HEAD CT FINDINGS 213
injury: an Eastern Association for the Surgery of Trauma practice
management guideline. J. Trauma Acute Care Surg. 73, Suppl 4,
S307–S314.
19. Papa, L., Lewis, L.M., Falk, J.L., Zhang, Z., Silvestri, S., Giordano, P.,
Brophy, G.M., Demery, J.A., Dixit, N.K., Ferguson, I., Liu, M.C., Mo,
J., Akinyi, L., Schmid, K., Mondello, S., Robertson, C.S., Tortella,
F.C., Hayes, R.L., and Wang, K.K. (2012). Elevated levels of serum
glial fibrillary acidic protein breakdown products in mild and mod-
erate traumatic brain injury are associated with intracranial lesions and
neurosurgical intervention. Ann. Emerg. Med. 59, 471–483.
20. McMahon, P.J., Panczykowski, D.M., Yue, J.K., Puccio, A.M., Inoue,
T., Sorani, M.D., Lingsma, H.F., Maas, A.I., Valadka, A.B., Yuh, E.L.,
Mukherjee, P., Manley, G.T., Okonkwo, D.O., Casey, S.S., Cheong, M.,
Cooper, S.R., Dams-O’Connor, K., Gordon, W.A., Hricik, A.J., Law-
less, K., Menon, D., Schnyer, D.M., and Vassar, M.J. (2015). Mea-
surement of the glial fibrillary acidic protein and its breakdown products
GFAP-BDP biomarker for the detection of traumatic brain injury
compared to computed tomography and magnetic resonance imaging. J.
Neurotrauma 32, 527–533.
21. Wilkinson, K.D., Lee, K.M., Deshpande, S., Duerksen-Hughes, P.,
Boss, J.M., and Pohl, J. (1989). The neuron-specific protein PGP 9.5 is
a ubiquitin carboxyl-terminal hydrolase. Science 246, 670–673.
22. Mondello, S., Muller, U., Jeromin, A., Streeter, J., Hayes, R.L. and
Wang, K.K. (2011). Blood-based diagnostics of traumatic brain in-
juries. Expert Rev. Mol. Diagn. 11, 65–78.
23. Papa, L., Lewis, L.M., Silvestri, S., Falk, J.L., Giordano, P., Brophy,
G.M., Demery, J.A., Liu, M.C., Mo, J., Akinyi, L., Mondello, S.,
Schmid, K., Robertson, C.S., Tortella, F.C., Hayes, R.L., and Wang,
K.K. (2012). Serum levels of ubiquitin C-terminal hydrolase distin-
guish mild traumatic brain injury from trauma controls and are ele-
vated in mild and moderate traumatic brain injury patients with
intracranial lesions and neurosurgical intervention. J. Trauma Acute
Care Surg. 72, 1335–1344.
24. Bazarian, J.J., Blyth, B.J., He, H., Mookerjee, S., Jones, C., Kiechle,
K., Moynihan, R., Wojcik, S.M., Grant, W.D., Secreti, L.M., Triner,
W., Moscati, R., Leinhart, A., Ellis, G.L., and Khan, J. (2013).
Classification accuracy of serum Apo A-I and S100B for the diagnosis
of mild traumatic brain injury and prediction of abnormal initial head
computed tomography scan. J. Neurotrauma 30, 1747–1754.
25. Florkowski, C.M. (2008). Sensitivity, specificity, receiver-operating char-
acteristic (ROC) curves and likelihood ratios: communicating the perfor-
mance of diagnostic tests. Clin. Biochem. Rev. 29, Suppl 1, S83–S87.
26. DeLong, E.R., DeLong, D.M., and Clarke-Pearson, D.L. (1988).
Comparing the areas under two or more correlated receiver operating
characteristic curves: a nonparametric approach. Biometrics 44, 837–845.
27. Bossuyt, P.M., Reitsma, J.B., Bruns, D.E., Gatsonis, C.A., Glasziou, P.P.,
Irwig, L.M., Moher, D., Rennie, D., de Vet, H.C., and Lijmer, J.G.
(2003). The STARD statement for reporting studies of diagnostic accu-
racy: explanation and elaboration. Ann. Intern. Med. 138, W1–W12.
28. Sauerbrei, W., Abrahamowicz, M., Altman, D.G., le Cessie, S., and
Carpenter, J. (2014). STRengthening analytical thinking for observa-
tional studies: STRATOS initiative. Stat. Med. 33, 5413–5432.
29. Kou, Z., Gattu, R., Kobeissy, F., Welch, R.D., O’Neil, B.J., Woodard,
J.L., Ayaz, S.I., Kulek, A., Kas-Shamoun, R., Mika, V., Zuk, C.,
Tomasello, F., and Mondello, S. (2013). Combining biochemical and
imaging markers to improve diagnosis and characterization of mild
traumatic brain injury in the acute setting: results from a pilot study.
PloS One 8, e80296.
30. Korevaar, D.A., van Enst, W.A., Spijker, R., Bossuyt, P.M., and
Hooft, L. (2014). Reporting quality of diagnostic accuracy studies: a
systematic review and meta-analysis of investigations on adherence to
STARD. Evid. Based Med. 19, 47–54.
31. Smits, M., Dippel, D.W., de Haan, G.G., Dekker, H.M., Vos, P.E.,
Kool, D.R., Nederkoorn, P.J., Hofman, P.A., Twijnstra, A., Tanghe,
H.L., and Hunink, M.G. (2005). External validation of the Canadian
CT Head Rule and the New Orleans Criteria for CT scanning in
patients with minor head injury. JAMA 294, 1519–1525.
32. Stiell, I.G., Clement, C.M., Rowe, B.H., Schull, M.J., Brison, R., Cass,
D., Eisenhauer, M.A., McKnight, R.D., Bandiera, G., Holroyd, B.,
Lee, J.S., Dreyer, J., Worthington, J.R., Reardon, M., Greenberg, G.,
Lesiuk, H., MacPhail, I., and Wells, G.A. (2005). Comparison of the
Canadian CT Head Rule and the New Orleans Criteria in patients with
minor head injury. JAMA 294, 1511–1518.
33. Stiell, I.G., Clement, C.M., Grimshaw, J.M., Brison, R.J., Rowe, B.H.,
Lee, J.S., Shah, A., Brehaut, J., Holroyd, B.R., Schull, M.J.,
McKnight, R.D., Eisenhauer, M.A., Dreyer, J., Letovsky, E., Rutledge,
T., Macphail, I., Ross, S., Perry, J.J., Ip, U., Lesiuk, H., Bennett, C.,
and Wells, G.A. (2010). A prospective cluster-randomized trial to
implement the Canadian CT Head Rule in emergency departments.
CMAJ 182, 1527–1532.
34. Initiative to Reduce Unnecessary Radiation Exposure from Medical
Imaging-February 2010. Center for Devices and Radiological Health-
U.S. Food and Drug Administration. Available at: http://www.fda.gov/
downloads/Radiation-EmittingProducts/RadiationSafety/RadiationDose
Reduction/UCM200087.pdf. Accessed: October 17, 2015.
Address correspondence to:
Robert D. Welch, MD, MS
Department of Emergency Medicine
Wayne State University
Detroit, MI 48230
E-mail: rwelch@med.wayne.edu
214 WELCH ET AL.
